Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
A divided U.S. appeals court ruled on Tuesday that federal workers generally do not deserve extra pay for being exposed to the COVID-19 virus on the job.
Read Full NewsPreschool-aged children exposed to screens for extended daily periods face elevated prevalence of sleep disturbances.
Treatment rates for US adults with psychiatric disorders are modestly higher than in previous decades, but only a third receive minimally adequate care, new research shows.
An Australian-designed smartphone app uses personalized cognitive bias modification to help users reduce or avoid alcohol consumption.
In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.
Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.
1.
Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.
2.
WHO launches plan for free child cancer medicines
3.
Adjuvant Combination for Kidney Cancer Gets FDA's Blessing
4.
Some triple negative breast cancers might be avoided by longer breastfeeding
5.
In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.
1.
How AI is Transforming Diagnostics, Drug Discovery, and Personalized Oncology
2.
Everything You Need to Know About CA 19-9 and Cancer Diagnosis
3.
Unlocking the Potential of Lutathera: A Revolutionary Cancer Treatment
4.
Community Survivorship Networks for Long-Term Cancer Wellness
5.
Recent Advances in Paroxysmal Nocturnal Hemoglobinuria Research: Promising Therapies on the Horizon
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
2.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge